Immatics is a leading cancer immunotherapy company and the global leader in the discovery of novel targets and the development of TCR bispecifics for various types of cancer immunotherapies.
Such immunotherapies have the potential to revolutionize cancer treatment and offer patients significant improvements in the length and quality of their lives compared to today’s therapies. Our goal is to deliver a step change in cancer treatment through the introduction of novel and highly innovative new therapies that use the body’s own immune system to fight cancer.
Immatics’ partnering model is designed to generate significant value for our existing and future partners from its current pipeline of therapeutic cancer immunotherapies and from its world-leading discovery platform XPRESIDENT® enabling rapid generation of best in class cancer immunotherapeutics.
To learn more about partnering opportunities with immatics, please contact:
Immatics Biotechnologies GmbH
Business Development Group
Dr Rainer Kramer, CBO
February 1-3, New York, USA
-/ Immuno-Oncology 360°
March 7-8, New York, USA
-/ Cancer Progress by Defined Health
March 7-9, London, UK
-/ World ADOPT Summit 2017
March 20-22, Barcelona, Spain
-/ BioEurope Spring
April 1-5, Washington, D.C., USA
-/ AACR Annual Meeting 2017
April 24-26, Amsterdam, The Netherlands
-/ European Neoantigen Summit 2017
June 2-6, Chicago, USA
-/ ASCO Annual Meeting
June 19-22, San Diego (CA), USA
-/ BIO International Convention